Clinical trials: Biological Availability
Healthy
Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study
The object of this study is to compare the relative bioavailability of lansoprazole 30 mg delayed-release capsules (manufactured by TEVA Pharmaceutical Industries, Ltd.
- Trial name
- NCT01046253
- Testing
- Lansoprazole, Prevacid®
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy Volunteers
A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants
The purpose of this study is to assess the oral BA of TAK-831 T3 tablet formulation relative to TAK-831 T2 tablet formulation under fasting conditions and to assess the effect of food on the pharmacokinetics (PK) of TAK-831 T3…
- Trial name
- NCT03706469
- Testing
- TAK-831 T2, TAK-831 T3
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Healthy
Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting
The objective of this study is to compare the relative bioavailability of cefdinir for oral suspension 250 mg/5mL (manufactured and distributed by TEVA Pharmaceuticals USA) with that of OMNICEF® for oral suspension, 250 mg/5mL…
- Trial name
- NCT00835549
- Testing
- Cefdinir for oral suspension 250 mg/5mL, OMNICEF® for oral suspension 250 mg/5mL
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions
This study will compare the relative bioavailability of 500 mg Divalproex Sodium Delayed-Release Tablets with that of 500 mg Depakote® Tablets following a single oral dose (1 x 500 mg tablets) in healthy subjects under…
- Trial name
- NCT00834990
- Testing
- divalproex sodium, Depakote®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
RDEA3170 Tablet and Capsule Bioavailability Study
The purpose of this study is to determine the relative bioavailability of RDEA3170 capsules compared with RDEA3170 tablets.
- Trial name
- NCT02448368
- Testing
- RDEA3170,10 mg, RDEA3170, 2.5 mg, RDEA3170, 5 mg
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Ardea Biosciences, Inc.
Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer.
- Conditions
- Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma, Advanced Vaginal Adenocarcinoma
- Trial name
- NCT02595879
- Testing
- Biospecimen Collection, Brachytherapy, Cisplatin
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19.
- Trial name
- NCT05580003
- Testing
- PF-07817883, Midazolam, Moxifloxacin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cytomegalovirus Infections
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
This study will assess the relative bioavailability of ganciclovir from the pro-drug valganciclovir in lung transplant recipients with or without cystic fibrosis.
- Trial name
- NCT00377741
- Testing
- valganciclovir [Valcyte]
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Biological Availability
A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
This trial is designed to compare the rate and extent of absorption of four different formulations of zavegepant. 52 healthy male and female volunteers will receive a single dose of each formulation at least 7 days apart over a…
- Trial name
- NCT06137703
- Testing
- Zavegepant 100mg non-enteric coated soft gel capsule, Zavegepant 100mg immediate release tablet, Zavegepant 2 x 100mg immediate release tablets
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers
This is a single centre, open label, randomized, two-treatment, two-period, two-sequence, single dose crossover food effect study in 18 subjects.
- Trial name
- NCT02690727
- Testing
- RP6530
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Rhizen Pharmaceuticals SA
Healthy
A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood
The main objective of this trial is to investigate the absolute bioavailability of BI 1265162 following administration of oral solution and inhaled (with and without charcoal) via Respimat.
- Trial name
- NCT03907280
- Testing
- BI 1265162 (T1), BI 1265162 (T2), BI 1265162 (R)
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Nonhematologic Malignancies, Lymphoma
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
This is an open-label, multicenter, sequential, 5-arm, phase 1 study of oral IXAZOMIB designed to assess drug-drug interaction with ketoconazole (Arm 1), the relative bioavailability of 2 capsule formulations of IXAZOMIB (Arm 2)…
- Trial name
- NCT01454076
- Testing
- Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy
Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers
The objective of the study is to investigate the relative bioavailability of the final tablet formulation (FF) of BI 10773 in comparison to the tablet formulation 2 (TF2).
- Trial name
- NCT01242176
- Testing
- BI 10773 XX (Trial Formulation 2), BI 10773 (Final Formulation)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule
The purpose of this study is to assess the effect of antacid administration, and its timing, on the bioavailability of a single dose of febuxostat extended-release (XR) 80 mg.
- Trial name
- NCT02382640
- Testing
- Febuxostat XR, Maalox Advance Regular Strength liquid
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Drug Interaction Study of Digoxin and BI 10773
The objective of the study is to investigate the relative bioavailability of digoxin after concomitant multiple oral administration of BI 10773 and a single dose of digoxin in comparison to digoxin given alone to healthy male and…
- Trial name
- NCT01306175
- Testing
- Digoxin plus BI 10773, Digoxin
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease
A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition
This study is intended to assess the relative bioavailability between the (extended-release) ER8 capsule formulation (the formulation that is currently used for verinurad development) given under fasted conditions and 2 new…
- Trial name
- NCT04024501
- Testing
- Verinurad ER8 capsule formulation (fasted), Verinurad A-capsule formulation (fasted), Verinurad A-capsule formulation (fed)
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study in Healthy Men and Women to Test if Taking Different Formulations of BI 730357 Tablets Influences the Amount of BI 730357 in the Blood
The main objective of Trial Parts 1 and 2 is to investigate the relative bioavailability of two tablet strengths (low dose and high dose) of the intended Commercial Formulation of BI 730357 (Test, T) versus with the corresponding…
- Trial name
- NCT03886272
- Testing
- BI 730357 (Test), BI 730357 (Reference)
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants
The purpose of this study is to assess the relative bioavailability of solid oral formulations of TAK-020 in comparison with single dose of TAK-020 oral solution formulation and to evaluate the food effect and potentially the…
- Trial name
- NCT02723201
- Testing
- TAK-020 Captisol Oral Solution, TAK-020 CCT, TAK-020 SDT
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers
To investigate the safety and tolerability of BI 416970 and to assess the pharmacokinetics (PK) of single rising doses of BI 416970. A further objective is to assess the influence of CYP2C9 phenotype on the PK of BI 416970.
- Trial name
- NCT02093819
- Testing
- BI 416970
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity Adult Onset
Bioavailability of SPMs in Obese Humans
Research Question: Does 4 weeks of supplementation with 'SPM Active' lead to a statistically significant increase in plasma SPM concentration for obese human subjects? Primary Aim 1: To compare plasma SPM concentrations and…
- Trial name
- NCT04701138
- Testing
- SPM Active
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill